SCHEMBL6733725

SCHEMBL6733725

CS(=O)(=O)c1cc(F)c(-c2csc(=O)n2-c2cccc(OC(F)(F)F)c2)cc1F

nearest known ligand 0.35

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.35
PIM1 P11309 2/20 0.33
PIM2 Q9P1W9 2/20 0.33
CACNA1B Q00975 1/20 0.33
SCN9A Q15858 2/20 0.32
CHRM5 P08912 2/20 0.32
PDE10A Q9Y233 2/20 0.32
NR1H2 P55055 5/20 0.32
NR1H3 Q13133 5/20 0.32
SLC22A12 Q96S37 1/20 0.31
NOTUM Q6P988 1/20 0.31
GRM5 P41594 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6729466 0.90 PTGES2 (0.36) KAT6APIM1PIM2SCN9APDE10A
SCHEMBL6739915 0.90 POLB (0.37) SCN9A
SCHEMBL6725490 0.86 PIM1 (0.35) KAT6APIM1PIM2CACNA1BCHRM5
SCHEMBL6736443 0.86 CYP1A2 (0.38) SCN9ANR1H2NR1H3NOTUM
SCHEMBL6731817 0.85 PTGS2 (0.38)
SCHEMBL6729181 0.84
SCHEMBL6728672 0.84 MCHR1 (0.33) SCN9ANR1H2NR1H3
SCHEMBL6737579 0.84 MAPT (0.35)
SCHEMBL6731937 0.84 ALDH1A1 (0.39)
SCHEMBL6739351 0.84 ACLY (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 KAT6A 3144/4885PIM1 2966/4885PIM2 2864/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 KAT6A 3144/4885PIM1 2966/4885PIM2 2864/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 KAT6A 3144/4885PIM1 2966/4885PIM2 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.